[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490889":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":60,"collaborators":62,"id":66,"slug":26,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":26,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Empagliflozin or Placebo in Acute","EXPERIMENTAL","Acute phase: Participants will receive 25 mg empagliflozin once on Day 0 or Day 7. Participants receive empaglifozin or placebo on Day 0. On Day 7, they will be crossed over to the alternate treatment.",[13],"Drug: Empagliflozin 25 mg vs Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Empagliflozin in Chronic","ACTIVE_COMPARATOR","Chronic phase: On day 8, all participants will receive 10 mg empagliflozin 10 mg x 8 weeks",[19],"Drug: Empagliflozin 10 MG",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Empagliflozin 25 mg vs Placebo","Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Empagliflozin 10 MG","Chronic Study- Empagliflozin 10 mg for 8 weeks",[15],[32],{"name":33,"affiliation":5,"role":34},"Jeffrey Testani, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Veena Rao, PHD","CONTACT","203-737-3571","veena.s.rao@yale.edu",{"name":42,"role":38,"phone":39,"phoneExt":26,"email":43},"Kara Otis","kara.otis@yale.edu",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","New Haven","Connecticut","06510","United States",{"type":52,"coordinates":53},"Point",[54,55],-72.92816,41.30815,{"lat":55,"lon":54},[58],{"name":59,"role":38,"phone":26,"phoneExt":26,"email":26},"Veena Rao, PhD",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[63],{"name":64,"class":65},"Boehringer Ingelheim","INDUSTRY","100490889",false,"NCT05671991","Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease","EMPA-PD","Inclusion Criteria\n\n1. Patients actively undergoing PD with a reliably functioning PD catheter\n2. Stable peritoneal dialysis prescription\n3. PD vintage \\> 3 months\n4. Age \\>18 years of age\n\nExclusion Criteria:\n\n1. History of type 1 diabetes, diabetic ketoacidosis, \"brittle\" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months\n2. Use of an SGLT2 inhibitor within the prior 30 days\n3. 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter\n4. Anemia with hemoglobin \\\u003C8g\u002FdL\n5. Inability to give written informed consent or follow study protocol\n6. Contraindication to receiving loop diuretics","ALL","18 Years",{"count":75,"type":76},30,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.\n\nThis is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week \"pre post\" open label extension in all 30 patients where they will receive empagliflozin daily.",[82],"End Stage Renal Disease on Dialysis",[84],"Peritoneal dialysis","2026-05-18",{"date":87,"type":88},"2026-05-22","ACTUAL",{"date":90,"type":88},"2023-03-01",{"date":92,"type":76},"2026-12-31",{"name":5,"class":6},1]